Measles, Mumps and Rubella vaccine (live) powder and solvent for solution for injection 0.5ml vials

IntroductionCommon warts are benign skin lesions caused by human papillomavirus (HPV) infection. They are often resistant to conventional treatments and may cause cosmetic and psychological distress. Immunotherapy is a promising alternative that stimulates the host immune system to clear the virus and the infected cells. This study compared the efficacy and safety of two immunotherapeutic agents, intralesional measles, mumps, and rubella (MMR) vaccine and intralesional vitamin D, in the treatment of common warts.MethodsThis was a single-blind randomised controlled trial conducted at a tertiary care hospital in Kolkata, India. Patients aged 12 years or older with common warts were randomly assigned to receive either intralesional MMR vaccine or intralesional vitamin D every 3 weeks for a maximum of three doses or until complete resolution, whichever was earlier. The primary outcome was the reduction in the size of the largest wart. Secondary outcomes included patients' and physicians' global assessment, complete response rate, adverse effects, and recurrence rate.ResultsA total of 36 patients were enrolled and analysed. Both MMR and vitamin D groups showed a significant reduction in the size of the largest wart throughout the treatment period (P P = 0.14). The recurrence rate was low in both groups (5.9% in the MMR group and 10.5% in the vitamin D group).ConclusionBoth intralesional MMR vaccine and intralesional vitamin D are effective and safe immunotherapeutic options for the treatment of common warts. MMR vaccine may have a slight advantage over vitamin D in terms of complete response rate; however, further studies with larger sample sizes and longer follow-ups are needed to confirm this finding.

Abstract licence: CC BY-NC-SA

Background Warts are prevalent distressing skin growths caused by the human papillomavirus (HPV). These growths are commonly addressed using methods that destroy the tissue, including chemical cautery, electrocautery, or cryotherapy. These methods have many side effects in contrast to intralesional immunotherapy. Objectives This study was conducted to assess the effectiveness, safety, and tolerability of utilising the intralesional measles, mumps, and rubella (MMR) vaccine compared to vitamin D in warts treatment. Methods This randomised clinical trial enrolled 112 participants presenting with multiple warts. The participants were sub-divided into two groups through a random allocation process. Group Ⅰ (n=56) was administered 0.3 mL intralesional MMR vaccine, whereas group Ⅱ (n=56) was administered 0.3 mL intralesional vitamin D3 (equivalent to 15000 IU cholecalciferol). The injection was administered every two weeks into the most noticeable wart, requiring no more than five sessions until improvement. A follow-up period of six months was conducted after the final treatment session. Results A significantly higher percentage of complete response was noticed in the MMR group (80.4%) as compared with the vitamin D group (66.1%). Both groups had an average of four sessions, showing no significant difference. Regarding adverse effects, the MMR group demonstrated a significantly greater incidence of mild pain (96.4%) and injection site itching (12.5%) compared with the vitamin D group. After 6 months of follow-up, no significant difference was noticed in recurrence rates in both groups (3 cases; 5.4% in the vitamin D vs. 2 cases; 3.6% in the MMR group). Conclusion Intralesional MMR demonstrates greater efficacy than vitamin D in treating warts but with a higher incidence of tolerable side effects.

Abstract licence: CC BY-NC-SA